MergerLinks Header Logo

Submit Deal

Submit Deal

Cover Image Amit Sinha
Amit SinhaGOLDMAN SACHS ALTERNATIVES

Amit Sinha

Managing Director and Head of Biotechnology at GOLDMAN SACHS ALTERNATIVES

Investor

Deal Bio

Total Deals4
Valued Deals4
Total Value£ 6.12 B
Avg. Deal Size£ 1.53 B

Market Context

Sort

09 Apr 2018|United States|Biotechnology
Avexis
Novartis

Target: AVEXIS INC

Bidder: NOVARTIS AG

12 Service Providers

8 Target | 4 Bidder

60 Dealmakers

47 Target | 13 Bidder

£ 5.28 B

Value

08 May 2019|Switzerland|Biotechnology
Therachon Holding
Pfizer

Target: THERACHON HOLDING AG

Bidder: PFIZER INC

9 Service Providers

6 Target | 3 Bidder

48 Dealmakers

36 Target | 12 Bidder

£ 645 M

Value

10 May 2022|United States|Biotechnology
Moma Therapeutics
Rock Springs Capital

Target: MOMA THERAPEUTICS

Bidder: ROCK SPRINGS CAPITAL

15 Service Providers

2 Target | 13 Bidder

14 Dealmakers

2 Target | 12 Bidder

£ 121 M

Value

13 May 2024|United States|Biotechnology
Ajax Therapeutics
Goldman Sachs Alternatives

Target: AJAX THERAPEUTICS

Bidder: GOLDMAN SACHS ALTERNATIVES

5 Service Providers

3 Target | 2 Bidder

6 Dealmakers

3 Target | 3 Bidder

£ 75 M

Value

Privacy PolicyTerms of ServiceContact UsCookie Preferences

All rights reserved. Copyright © 2025 Datasite